- Home
- GLPG vs NHC Comparison
GLPG vs NHC Comparison
Compare GLPG & NHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- NHC
- Stock Information
- Founded
- GLPG 1999
- NHC 1971
- Country
- GLPG Belgium
- NHC United States
- Employees
- GLPG N/A
- NHC N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- NHC Hospital/Nursing Management
- Sector
- GLPG Health Care
- NHC Health Care
- Exchange
- GLPG Nasdaq
- NHC Nasdaq
- Market Cap
- GLPG 2.1B
- NHC 1.8B
- IPO Year
- GLPG 2005
- NHC N/A
- Fundamental
- Price
- GLPG $33.24
- NHC $119.51
- Analyst Decision
- GLPG Sell
- NHC
- Analyst Count
- GLPG 3
- NHC 0
- Target Price
- GLPG $26.00
- NHC N/A
- AVG Volume (30 Days)
- GLPG 162.5K
- NHC 46.6K
- Earning Date
- GLPG 10-29-2025
- NHC 11-07-2025
- Dividend Yield
- GLPG N/A
- NHC 2.22%
- EPS Growth
- GLPG N/A
- NHC 12.96
- EPS
- GLPG N/A
- NHC 6.70
- Revenue
- GLPG $323,674,692.00
- NHC $1,458,155,000.00
- Revenue This Year
- GLPG $1.77
- NHC N/A
- Revenue Next Year
- GLPG N/A
- NHC N/A
- P/E Ratio
- GLPG N/A
- NHC $17.21
- Revenue Growth
- GLPG 5.43
- NHC 24.46
- 52 Week Low
- GLPG $22.36
- NHC $89.14
- 52 Week High
- GLPG $33.86
- NHC $136.86
- Technical
- Relative Strength Index (RSI)
- GLPG 58.22
- NHC 71.14
- Support Level
- GLPG $31.49
- NHC $114.59
- Resistance Level
- GLPG $33.63
- NHC $122.10
- Average True Range (ATR)
- GLPG 0.68
- NHC 2.70
- MACD
- GLPG 0.01
- NHC -0.04
- Stochastic Oscillator
- GLPG 85.82
- NHC 76.15
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About NHC National HealthCare Corporation
National Healthcare Corp Provides long-term care facilities. Its principal business includes the operation of skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services, and Home care hospice services. Generating, a majority of its revenue from Inpatient services.